Synerkine Pharma, a biopharmaceutical company based in Leiden, has announced on Thursday that it has successfully secured €5.3M in an extension of its Series A financing.
The funding round was led by Flerie and was supported by new investors such as InnovationQuarter Capital and Utrecht Health Seed Fund, along with existing investor Thuja Capital.
The equity financing is accompanied by a matching innovation credit from Rijksdienst voor Ondernemend (RVO) Nederland – the Netherlands Enterprise Agency.
The announcement comes over a year after raising €3.5M in another Series A extension round of funding in December 2021. In 2019, the Dutch company raised €3.3M in its Series A round from Thuja Capital and others.